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Background & aims: Gestational diabetes mellitus (GDM) compromises the level of docosahexaenoic acid
(DHA) in phospholipids of maternal and fetal red blood cells and fetal plasma. This is of some concern
because of the importance of DHA for fetal neuro-visual development. We have investigated whether
this abnormality could be rectiﬁed by supplementation with DHA-enriched formula.
Methods: Womenwith GDM (n ¼ 138) recruited from Newham University Hospital, London received two
capsules of DHA-enriched formula (active-group) or high oleic acid sunﬂower seed oil (placebo-group)
from diagnosis until delivery. Maternal (baseline and delivery) and fetal (cord blood) red blood cell and
plasma phospholipid fatty acid composition, and neonatal anthropometry were assessed.
Results: One hundred and fourteen women (58 active, 56 placebo) completed the trial. The active-group
compared with the placebo-group had signiﬁcantly enhanced level of DHA in plasma phosphatidyl-
choline (4.5% vs 3.8%, P ¼ 0.011), red blood cell phosphatidylcholine (2.7% vs 2.2%, P ¼ 0.022) and
phosphatidylethoanolamine (9.5% vs 7.6%, P ¼ 0.002). There was no difference in cord plasma and red
blood cell phospholipid DHA between the two groups. The neonates of the two groups of women had
comparable anthropometric measurements at birth.
Conclusion: Daily supplementation of 600 mg DHA enhances maternal but not fetal DHA status in
pregnancy complicated by GDM. The inefﬁcacy of the supplement to improve fetal status suggests that
the transfer of DHA across the placenta maybe impaired in women with the condition. Regardless of the
mechanisms responsible for the impairment of the transfer, the ﬁnding has implications for the man-
agement of neonates of women with GDM because they are born with a reduced level of DHA and the
condition is thought to be associated with a risk of neuro-developmental deﬁcits. We suggest that babies
of women with GDM, particularly those not suckling, similar to the babies born prematurely require
formula milk fortiﬁed with a higher level of DHA.
© 2015 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.1. Introduction
The impacts of gestational diabetes mellitus (GDM) on short-
and long-term health of women and their offspring are increasinglyesearch Centre, Faculty of Life
sity, 166-220 Holloway Road,
4 20 7133 4682.
ju@gmail.com (Y. Min).
for Clinical Nutrition and Metabolrecognized [1]. In Europe, the estimated prevalence of GDM ranges
from 2 to 6% and it is expected to rise with increasing obesity, a
strong risk factor for developing the condition [2]. Other determi-
nant factors are a family history of type 2 diabetes, advanced
maternal age and ethnicity. Certain ethnic groups are more pre-
disposed to GDM [3].
We have previously reported that GDM reduces the levels of
docosahexaenoic acid (DHA) and arachidonic acid (AA) in maternal
red blood cell [4,5] and fetal red blood cell and plasma [5e7]ism. All rights reserved.
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acids of the omega-3 and omega-6 family, respectively, are vital
structural and functional components of cellular and sub-cellular
membranes as well as precursors of diverse bioactive compounds.
In addition, based on animal models of obesity and cell culture
studies, it is postulated that DHA might be a potent anti-adiposity
agent [8] and enhance glucose utilization by modulating insulin
secretion and action [9,10].
The importance of DHA and AA in fetal life has been extensively
documented [11,12]. Of these two fatty acids, DHA is considered to
be the most limiting nutrient in pregnancy and lactation because it
is scarce or absent in land animal and plant food sources. Moreover,
the synthesis of DHA from the parent compound a-linolenic acid is
inefﬁcient. In normal pregnancy, DHA is preferentially transferred
by placental selection from maternal to placental circulation.
However, recent studies have reported that the placental uptake
and transfer of DHA is impaired in pregnancy complicated by GDM
[13,14]. There are no published communications whether or not the
impact of this impairment could be ameliorated by DHA supple-
mentation. In this report, we present the ﬁndings of a randomized,
double-blind, placebo-controlled trial in which women with GDM
were supplemented with DHA-enriched formula or high oleic acid
sunﬂower seed oil. The primary outcome measure was the red
blood cell membrane phospholipid DHA levels in the women and
their neonates at delivery.
2. Materials and methods
The study was approved by East London & The City HA Local
Research Ethics Committee 3 (REC reference no. 06/Q0605/89) and
registered with ISRCTN Register (registration no. ISRCTN68997518).
Written informed consent was obtained from all participants and
the investigation was carried out in accordance with the principles
of the Declaration of Helsinki as revised in 2007. Participants,
midwives, and all investigators were blinded to allocation until all
the data collated and analyzed.
2.1. Subjects and intervention
The study was carried out in Newham Borough, an inner city
area of Greater London with a high proportion of immigrant com-
munity, predominantly South Asian and African/Caribbean ethnic
group. Subjects were recruited during their visit to the antenatal or
diabetic clinics at Newham University Hospital between October
2007 and February 2012. The inclusion criteria were 17e45 years
old womenwith singleton pregnancies diagnosedwith GDM. Those
who were planning to receive tocolytic or corticosteroid therapy or
had been taking omega-3 supplement during the period of time
leading to their current pregnancy were excluded. Because of the
high incidence of GDM and type 2 diabetes in the area, the hospital
tests for GDM for women with high risk factors for the condition
from early weeks of pregnancy. The test involves an overnight fast
followed by drinking a solution of 75 g of glucose and drawing
blood at 60 and 120 min for glucose determination. GDM is diag-
nosed if the glucose level at 120 min is greater than 7.8 mmol/l.
The eligible women who consented to participate in the study
were randomized to receive daily 2 capsules of either “DHA-
enriched formula” or “placebo (high oleic acid sunﬂower seed oil)”.
Each active supplement capsule contained 300mg of DHA, 42mg of
eicosapentaenoic acid (EPA) and 8.4 mg of AA, and placebo 721 mg
of oleic acid. Randomization was carried out using a random code
generated by the supplement provider (Equazen/Vifor Pharma Ltd.,
Glattbrugg, Switzerland). Both supplements contained vitamin E
(d-alpha tocopherol) as an antioxidant andwere encapsulated in an
identical oblong soft gelatin capsule (750 mg in size).2.2. Sample size
Sample size was calculated based on our previous caseecontrol
study [7] which found a 35% difference in red blood cell phospha-
tidylcholine DHA between neonates of pregnant womenwith GDM
(4.0%) and those without the condition (5.4%). We assumed that
supplementation of women with GDM with DHA-rich ﬁsh oil
would increase the level of the nutrient in their neonates to the
level of those born to women who had uncomplicated pregnancy.
The power calculation indicated that a minimum of 40 subjects
(neonates) per group would be required to detect the changes in
red blood cell phosphatidylcholine DHA level with 80% power. The
sample size and power calculationwas performed using G*Power 3
[15] and based on a two independent groups, two-tailed t-test with
an alpha of 0.05.2.3. Blood collection and fatty acid analysis
Non-fasting venous blood samples (5e10 ml) were obtained
from the subjects at recruitment (17the33rd gestational weeks) and
delivery (maternal and cord) in EDTA vacutainer tubes. Samples
collected during the day were transported promptly to the Lip-
idomics and Nutrition Research Centre (LNRC) laboratory for pro-
cessing. Blood samples collected at night or on weekends were
processed at the Pathology Laboratory, Newham University Hos-
pital and subsequently transported to the LNRC laboratory. All
samples were stored at 70 C until analysis.
Fatty acid composition of red blood cell and plasma phospho-
lipids was determined using the standardized method developed
by our laboratory [7]. Brieﬂy, total lipids were extracted by ho-
mogenizing the samples in chloroform and methanol, and the
phospholipid fractions from the resulting total lipid were separated
by thin-layer chromatography. Fatty acid methyl esters prepared
from the phospholipids were separated using a gaseliquid chro-
matograph (HRGC MEGA 2 Series; Fisons Instruments, Milan, Italy)
and quantiﬁed using a chromatography data system (Agilent
EZChrom Elite Chromatography Data System v3.2, Scientiﬁc Soft-
ware, Inc., Pleasanton, CA, USA).2.4. Neonatal anthropometric measurement
Weight and length of the newborn babies were recorded by a
midwife who attended the delivery as per routine practice and
head-, shoulder-, mid-arm-, and abdominal circumferences by
research midwives (JH and IN). Seca 210 portable measuring mat
and Seca 201 ergonomic circumference measuring tape (Seca UK,
Birmingham, UK) were used.2.5. Statistical analysis
Data are presented as mean ± standard deviation (SD), median
(range), and number of occurrence as appropriate and statistical
signiﬁcance was set at P < 0.05. All analyses were performed based
on intention-to-treat principle. Independent t-test was used to
compare the difference in fatty acids and anthropometric mea-
surement between the active and placebo groups. The differences
in pregnancy outcome were tested with Chi-square test. The
change in DHA level within the group (baseline versus delivery)
was assessed both by independent (including all subjects) and
paired-sample (including only matched samples) t-test. All ana-
lyses were carried out with IBM SPSS Statistics version 20 (IBM
Corporation, Armonk, NY, USA).
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One hundred thirty eight women with GDM were randomized
to receive either active or placebo, and 114 (58 active-group, 56
placebo-group) completed the trial (Fig. 1). The last delivery took
place in May 2012.
The ethnic composition of the groups was similar and reﬂected
the population diversity of the Borough (Table 1). 22.4% of the
active-group and 25.4% of the placebo-group had gestational dia-
betes in their previous pregnancy. Over 60% of womenwere treated
with oral hypoglycemic agents (active-group 49.3%; placebo-group
50.7%) or insulin (active-group 11.9%; placebo-group 14.1%). There
was awide variation in the duration of supplementation. This was a
result of number of women being diagnosed with GDM either early
or late stage of pregnancy. Five women (4 active and 1 placebo)
claimed to have taken occasionally omega-3 supplement purchased
from health shops during the course of the study. However, their
DHA and EPA levels were not different from the mean values of
their respective groups. Compliance was monitored by regular
home visits by the research midwives and telephone contact
(including out-of-ofﬁce hour), and by counting unused capsules
which the women are asked to bring with themwhen they come to
collect the next batch of supplements.
Pregnancy outcomes and neonatal anthropometry are shown in
Table 2. From the placebo-group, one woman had miscarriage and
another delivered stillborn baby, and there was one case of cleft lip
and palate in the active-group. There was no difference in the
anthropometric measurement between the two groups. However,
the numbers of babies born at preterm and low birth weight were
higher in the active-group but the difference did not reach statis-
tical signiﬁcance level.
Percentages of the major fatty acids of plasma and red blood cell
phosphatidylcholine and red blood cell phosphatidylethanolamine
are presented in Table 3. There was no difference in fatty acidEnrolle
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Fig. 1. Flowchart of participants duringcomposition of plasma or red blood cell phospholipids between
those randomized to receive active supplement or placebo at
baseline. At delivery, the women supplemented with active sup-
plement compared with those who were given placebo had higher
level of DHA in plasma phosphatidylcholine (P ¼ 0.011), red blood
cell phosphatidylcholine (P ¼ 0.022) and phosphatidylethanol-
amine (P ¼ 0.002), and a lower level of AA in plasma phosphati-
dylcholine (P ¼ 0.045). Both groups had comparable levels of
saturated andmonounsaturated fatty acids in plasma and red blood
cell phospholipids. Moreover, they had a similar red blood cell
unsaturation index (sum of the % unsaturated fatty acids multiplied
by their number of double bonds).
Within-group baseline and delivery comparison in plasma
phosphatidylcholine revealed an increase in palmitic (P < 0.01) and
oleic (P < 0.001) acids and decrease in stearic acid (P < 0.001) in
both groups. There was a decrease in the level of DHA in the
placebo-group (17.4%, P ¼ 0.009) and AA in the active-group
(12.3%, P ¼ 0.000). The level of DHA in the active-group and AA
in the placebo-group did not change between baseline and delivery.
In red blood cell phosphatidylcholine, oleic and stearic acids in
the active-group (P < 0.05) and a-linolenic acid, EPA, DHA in the
placebo-group (P < 0.01) decreased between baseline and delivery.
The changes in red blood cell phosphatidylethanolamine fatty acids
with the progress of pregnancy mirrored broadly that of plasma
phosphatidylcholine. There was an increase in saturated (P < 0.05)
and monounsaturated (P < 0.01) fatty acids, and a decrease in AA
(P < 0.01) in both groups of women. The level of EPA and DHA did
not change between baseline and delivery in the womenwho were
given active supplement. In contrast, the level of both fatty acids
decreased signiﬁcantly at delivery in those who received placebo
(P ¼ 0.001). These changes led to a reduced unsaturation index
(P < 0.01) in both groups.
Plasma and red blood cell phospholipid fatty acid proﬁles of the
neonates from both groups were similar (Table 4). Within the actived (n=143)
Placebo-group 
(n=71)
Lost to follow-up (n=13)
• 8 declined to continue
• 5 moved out of the area 
Live births (n=56)
• 14 deliveries were missed (no maternal 
& cord samples available)
5 excluded due to not 
meeting inclusion criteria 
or declined
sed (n=138)
1 stillbirth & 1 miscarriage 
the course of the randomized trial.
Table 1
Demographic and obstetric characteristics of the participants.a
Active-group Placebo-group
Number of participants (n) 67 71
Gestation at recruitment (weeks)b 28.3 (17.4e33.4) 28.3 (17.0e32.9)
Age (years)b 31.0 (21.0e41.0) 32.0 (21.0e44.0)
Pre-pregnancy weight (kg)c 73.9 ± 15.8 72.6 ± 15.3
Height (m)c 1.6 ± 0.1 1.6 ± 0.1
Pre-pregnancy BMIc,d 29.0 ± 5.6 29.2 ± 5.7
25.0 17 19
25.1e30.0 23 24
30.1 27 28
Ethnicity (n)e
Asian 40 44
African/Afro-Caribbean 18 18
Caucasian 5 5
Others 4 4
Parity (n)f
0 33 24
1 - 3 27 40
4 6 5
Smoker (n) 2 0
Planned pregnancy (n) 42 37
GDM in previous pregnancy (n) 15 18
Folic acid use (n) 18 18
Glucose tolerance test
Gestation (weeks)b 18.7 (11.4e30.1) 20.6 (13.3e31.9)
Glucose at 0 min (mmol)c 5.6 ± 1.6 5.5 ± 1.3
Glucose at 120 min (mmol)c 9.6 ± 2.2 9.3 ± 1.8
Diabetes treatment (n)
Diet only 26 24
Oral hypoglycemic agents 33 36
Insulin 8 10
Oral hypoglycemic agents þ insulin e 1
Family history of diabetes (n)
Mother 29 21
Father 20 26
Both parent 6 12
a No statistical test was performed as per CONSORT guidelines.
b Gestation week and age are presented as median (min e max).
c Values are presented as mean ± SD.
d BMI, body mass index (kg/m2).
e The UK Home Ofﬁce's classiﬁcation for an individual's ethnicity according to
person's self-deﬁnition was used; Asian (Bangladesh, Bengali, Sri Lankan, Indian,
Pakistani), African/Afro-Caribbean (Black African, Black British, Caribbean, Afro-
Caribbean), Caucasian (English, Polish, Irish, European), Others (Filipino, Arab,
North African, Latin American, Mixed-race).
f Information was not available from 3women (1 active-group, 2 placebo-group).
Table 2
Pregnancy outcomes and anthropometric measurement.a
Active-group Placebo-groupb
Live births (n)c 58 56
Gestation at delivery (weeks)d 38.1 (33.3e41.1) 38.1 (35.9e41.1)
Supplementation duration (weeks)d 10.0 (4.0e22.0) 10.0 (4.0e20.0)
Gender (n)
Male 29 32
Female 29 24
Delivery method (n)
Vaginal - Spontaneous 19 11
Assisted 5 3
Induced 6 13
Caesarean section - Elective 7 9
Emergency 21 20
Preterm birth (n)e 12 5
Late-preterm birth (n)f 10 5
Low birth weight (n)g 8 4
Macrosomia (n)h 3 3
Neonatal hypoglycemia (n) 2 3
Congenital defect (n)i 1 0
Anthropometric measurementj
Weight (kg) 3.2 ± 0.6 3.1 ± 0.4
Length (cm) 49.0 ± 7.8 50.3 ± 5.7
Head circumference (cm) 33.9 ± 1.6 33.8 ± 2.5
Shoulder circumference (cm) 36.3 ± 5.5 36.0 ± 5.6
Mid-arm circumference (cm) 11.9 ± 2.1 11.5 ± 2.6
Abdominal circumference (cm) 33.1 ± 4.1 33.0 ± 4.3
a The pregnancy outcome and neonatal anthropometric measurement did not
differ between active and placebo groups.
b There was one stillbirth and one miscarriage in the placebo-group.
c This number included all the subjects who completed the supplementation
regardless of the availability of blood samples at delivery.
d Gestation week at delivery and supplementation duration are given median
(min e max).
e Preterm birth; born less than 37 weeks of gestation.
f Late-preterm birth; born between 34 0/7 weeks and 36 6/7 weeks of gestation.
g Low birth weight; birth weight less than 2.5 kg.
h Macrosomia; body weight greater than 4 kg.
i One baby from the active-group was born with cleft lip and palate.
j Anthropometric measurement are presented as mean ± SD. The measurement
for one baby from the active-group was not obtained.
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mothers had less than 10 weeks of supplement did not differ from
those supplemented for a longer period.4. Discussion
Mature red blood cells have a limited ability of synthesizing
phospholipids de novo from glycerol or sphingosine backbone.
Therefore, the renewal/remodeling of red blood cell membrane
phospholipids, which occurs continuously, is reliant on plasma lipid
pool. The renewal mechanisms include transfer of fatty acids from
plasma neutral lipids to phosphatidylethanolamine through phos-
phatidylcholine [16], deacylationereacylation cycles of endogenous
fatty acids and passive exchange of intact phospholipids, primarily
phosphatidylcholine, with plasma phospholipids [17]. Hence, it is
evident that the fatty acid moieties of red blood cell phospholipids
have their origin in plasma lipids [18] in individuals without
underlining clinical conditions.
We have previously observed that womenwith GDM, regardless
of their ethnic origin and dietary background, had reduced level of
DHA in red blood cell but not plasma phospholipids [4,5,7]. These
ﬁndings led us to postulate “the incorporation of DHA from plasmainto red blood cells is compromised in women with the condition
due to hyperglycemia”. In addition, we postulated “this impairment
is ameliorated by a rigorous glycemic control”. Consistent with our
postulation, DHA supplementation enriched the level of the fatty
acid in plasma and red blood cell phospholipids in the GDMwomen
whose blood glucose was well-controlled by using diet, oral hy-
poglycemic agents or/and insulin.
Maternal DHA level declines in the later part of pregnancy in
healthy “well-nourished” women without obstetric complications.
This is often described as a physiological response to pregnancy.
Therewas no such decrease in thewomenwith gestational diabetes
supplemented with DHA-enriched formula. Moreover, the phe-
nomenon does not occur in pregnant women from communities
who consume high amounts of ﬁsh and seafood [19], or in those
supplemented with ﬁsh oil or ﬁsh [20,21]. Hence, the decline of
DHA in pregnancy signiﬁes an imbalance between maternal status
and mother-fetus requirement.
Working groups have recommended that expectant and nursing
mothers have to consume 300 mg of DHA daily [22]. The recom-
mended value which is based on breast milk, and maternal,
neonatal and infant blood DHA data from supplemented and
unsupplmented women primarily from the developed countries
are essentially guesstimates. In our study of a cohort of unsuppl-
mented pregnant British and Sudanesewomen, the levels of DHA in
maternal plasma phosphatidylcholine were 4.3% [7] and 2.3%
(Nyuar KB and Ghebremeskel K, unpublished data) respectively.
Table 3
Maternal plasma and red blood cell phospholipid fatty acid composition at baseline and delivery.a
Baseline Delivery Baseline vs deliveryc (P value)
Active-group (n 67) Placebo-group (n 71) P valueb Active-group (n 46) Placebo-group (n 42) P valueb Active-group Placebo-group
Plasma phosphatidylcholine
Palmitic 29.8 ± 3.6 30.4 ± 3.1 NS 32.0 ± 2.1 32.7 ± 2.6 NS 0.000 0.000
Stearic 10.2 ± 1.4 10.0 ± 1.2 NS 9.1 ± 1.0 9.0 ± 1.2 NS 0.000 0.000
Oleic 10.9 ± 3.8 10.7 ± 2.0 NS 13.0 ± 2.4 13.0 ± 2.6 NS 0.001 0.000
Linoleic 24.7 ± 3.5 24.8 ± 3.0 NS 23.7 ± 3.0 22.7 ± 3.6 NS NS 0.002
a-linolenic 0.3 ± 0.1 0.3 ± 0.1 NS 0.4 ± 0.1 0.3 ± 0.1 NS NS NS
Arachidonic 10.6 ± 2.1 10.6 ± 1.9 NS 9.3 ± 1.8 10.1 ± 2.3 0.045 0.000 NS
Eicosapentaenoic 0.7 ± 0.7 0.8 ± 0.7 NS 0.7 ± 0.4 0.6 ± 0.5 NS NS NS
Docosahexaenoic 4.5 ± 1.0 4.6 ± 1.5 NS 4.5 ± 1.0 3.8 ± 1.2 0.011 NS 0.009
S Saturates 41.0 ± 3.4 41.3 ± 2.5 NS 42.0 ± 1.9 42.6 ± 2.4 NS NS 0.006
S Monoenes 11.5 ± 4.0 11.4 ± 2.1 NS 13.9 ± 2.5 13.9 ± 2.7 NS 0.001 0.000
S n-6 40.4 ± 3.4 40.0 ± 3.5 NS 37.2 ± 2.8 37.2 ± 4.0 NS 0.000 0.000
S n-3 6.1 ± 1.5 6.3 ± 2.3 NS 6.0 ± 1.4 5.3 ± 1.7 0.031 NS 0.015
S n-6/S n-3 ratio 7.1 ± 1.9 7.3 ± 3.4 NS 6.5 ± 1.9 7.9 ± 3.4 0.028 NS NS
Red blood cell phosphatidylcholine
Palmitic 36.4 ± 2.3 36.3 ± 3.4 NS 35.8 ± 4.0 36.4 ± 4.3 NS NS NS
Stearic 8.1 ± 1.2 8.1 ± 1.6 NS 8.3 ± 1.5 8.5 ± 1.7 NS 0.018 NS
Oleic 15.5 ± 1.6 15.5 ± 2.3 NS 16.9 ± 2.3 17.0 ± 2.8 NS 0.000 0.000
Linoleic 22.5 ± 2.8 21.8 ± 3.7 NS 22.4 ± 3.3 21.2 ± 4.2 NS NS NS
a-linolenic 0.2 ± 0.1 0.2 ± 0.1 NS 0.2 ± 0.1 0.2 ± 0.1 NS NS 0.007
Arachidonic 7.2 ± 1.5 7.5 ± 2.0 NS 6.8 ± 1.8 7.3 ± 2.7 NS NS NS
Eicosapentaenoic 0.4 ± 0.4 0.6 ± 0.5 NS 0.5 ± 0.3 0.4 ± 0.3 NS NS 0.003
Docosahexaenoic 2.5 ± 0.7 2.7 ± 1.0 NS 2.7 ± 1.0 2.2 ± 1.0 0.022 NS 0.002
S Saturates 45.5 ± 2.2 45.3 ± 3.6 NS 44.9 ± 4.1 45.7 ± 4.5 NS NS NS
S Monoenes 16.1 ± 1.7 16.2 ± 2.3 NS 17.6 ± 2.3 17.7 ± 3.0 NS 0.000 0.000
S n-6 33.4 ± 2.7 33.0 ± 4.1 NS 32.7 ± 4.5 32.0 ± 5.9 NS NS 0.036
S n-3 3.6 ± 1.0 4.0 ± 1.5 NS 3.8 ± 1.3 3.2 ± 1.4 0.044 NS 0.000
S n-6/S n-3 ratio 10.3 ± 5.0 9.7 ± 4.5 NS 9.6 ± 3.4 11.6 ± 4.7 0.03 NS 0.023
Unsaturation indexd 121.5 ± 8.2 123.3 ± 14.7 NS 121.5 ± 15.7 118.1 ± 19.1 NS NS 0.036
Red blood cell phosphatidylethanolamine
Palmitic 14.9 ± 1.6 14.9 ± 1.8 NS 15.9 ± 2.8 16.5 ± 3.7 NS 0.02 0.004
Stearic 5.5 ± 0.9 5.6 ± 1.1 NS 6.3 ± 1.3 6.5 ± 1.7 NS 0.000 0.003
Oleic 16.4 ± 1.2 16.4 ± 1.4 NS 17.9 ± 2.9 18.6 ± 4.5 NS 0.004 0.009
Linoleic 5.5 ± 1.2 5.6 ± 1.4 NS 6.0 ± 1.4 6.1 ± 1.6 NS 0.02 NS
a-linolenic 0.2 ± 0.1 0.2 ± 0.1 NS 0.2 ± 0.1 0.2 ± 0.1 NS NS NS
Arachidonic 19.7 ± 2.4 19.4 ± 2.6 NS 17.7 ± 3.3 17.7 ± 4.1 NS 0.000 0.002
Eicosapentaenoic 0.9 ± 0.5 1.0 ± 0.7 NS 0.9 ± 0.6 0.8 ± 0.7 NS NS 0.001
Docosahexaenoic 8.8 ± 1.9 9.2 ± 2.2 NS 9.5 ± 2.3 7.6 ± 3.0 0.002 NS 0.001
S Saturates 21.3 ± 2.7 21.3 ± 1.6 NS 23.2 ± 4.0 24.0 ± 5.3 NS 0.001 0.001
S Monoenes 16.9 ± 1.3 17.0 ± 1.5 NS 18.5 ± 2.9 19.2 ± 4.5 NS 0.004 0.011
S n-6 33.5 ± 3.5 33.4 ± 4.2 NS 31.1 ± 4.6 31.6 ± 6.6 NS 0.000 0.003
S n-3 13.6 ± 2.7 14.0 ± 3.4 NS 13.7 ± 3.2 11.7 ± 4.5 0.028 NS 0.001
S n-6/S n-3 ratio 2.6 ± 0.7 2.6 ± 1.1 NS 2.4 ± 0.7 3.5 ± 3.9 NS 0.047 NS
Unsaturation indexd 215.2 ± 12.5 217.6 ± 13.0 NS 207.1 ± 24.5 198.7 ± 33.6 NS 0.009 0.000
NS, not signiﬁcant (P > 0.05).
a Data are expressed as relative percentage of total fatty acids identiﬁed (% wt/wt).
b Independent t-test was used to compare the differences between the active and placebo groups at baseline and delivery.
c Paired t-test was used to compare the changes between the baseline and delivery within the group.
d Unsaturation index is the sum of the % unsaturated fatty acids multiplied by their number of double bonds.
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is whether supplementation of Sudanese pregnant women with
300 mg of DHA daily would be sufﬁcient to forestall the decline of
the fatty acid in late pregnancy. We suggest that the DHA
requirement for healthy pregnant women should be based on the
amount needed to prevent this decline.
Improved neonatal DHA status after maternal supplementation
with high DHA during uncomplicated pregnancies has been
consistently reported. Similarly, we have recently reported
maternal supplementation-induced enrichment of cord blood DHA
in pregnancy complicated by type 2 diabetes [23]. In this study, the
neonates of the DHA supplemented women did not have increased
level of the nutrient. The reason for this intriguing ﬁnding is not
clear since type 2 and GDM share similar metabolic features and
both groups of women were given 600 mg of DHA daily. However,
impaired placental uptake [13,14] and maternalefetal transfer [14]of DHA, and considerable placental abnormalities than in type 1
and 2 diabetes [24] have been reported in pregnancy complicated
by GDM. It is worth noting that the shorter supplementation
duration (median 10 weeks) in the current study compared with
our previous investigation of pregnant womenwith type 2 diabetes
(median 26 weeks) [23] could be germane to the outcome.
As in our previous studies [4,5], therewas a signiﬁcant decline in
the level of AA in red blood cell phosphatidylcholine in both groups
of women between diagnosis and delivery. Although the DHA-
enriched supplement contained about 2% of AA (% total fatty
acids), there was a similar decrease in plasma phosphatidylcholine
AA in the group who received DHA-enriched supplement. The
DHA þ EPA/AA ratio of the capsule was 26:1 and there is evidence
that supplementation-induced increase in tissue level of DHA, EPA
or DHA plus EPA is associated with a concomitant decrease in AA
[25]. Hence, it appears that AA in both plasma and red blood cell
Table 4
Neonatal plasma and red blood cell phospholipid fatty acid composition.a,b
Plasma phosphatidylcholine Red blood cell phosphatidylcholine Red blood cell
phosphatidylethanolamine
Active-group Placebo-group Active-group Placebo-group Active-group Placebo-group
Palmitic 30.3 ± 2.3 30.3 ± 2.1 36.8 ± 2.5 36.5 ± 2.9 17.8 ± 2.9 17.4 ± 2.6
Stearic 13.4 ± 1.8 13.3 ± 1.5 9.2 ± 1.4 9.6 ± 1.5 6.1 ± 1.7 5.8 ± 1.2
Oleic 12.0 ± 1.9 11.8 ± 1.9 18.2 ± 2.2 17.6 ± 1.9 13.8 ± 3.0 13.4 ± 2.5
Linoleic 10.3 ± 2.3 9.9 ± 2.6 9.3 ± 2.2 8.9 ± 1.4 2.5 ± 0.6 2.4 ± 0.5
a-linolenic 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.03 0.1 ± 0.03 0.1 ± 0.04
Arachidonic 16.9 ± 3.0 18.0 ± 3.4 13.4 ± 2.6 14.3 ± 2.6 23.8 ± 3.9 24.4 ± 3.0
Eicosapentaenoic 0.5 ± 0.3 0.5 ± 0.4 0.3 ± 0.2 0.3 ± 0.3 0.3 ± 0.2 0.3 ± 0.3
Docosahexaenoic 5.8 ± 1.7 5.5 ± 1.7 3.5 ± 1.2 3.4 ± 1.1 8.4 ± 1.9 8.2 ± 1.6
S Saturates 44.5 ± 2.3 44.4 ± 2.3 46.9 ± 2.8 47.0 ± 2.4 25.5 ± 3.7 24.7 ± 2.4
S Monoenes 13.0 ± 2.2 12.7 ± 2.0 19.2 ± 2.4 18.5 ± 2.0 14.4 ± 3.1 13.9 ± 2.6
S n-6 34.2 ± 3.3 34.8 ± 3.1 28.0 ± 3.9 28.6 ± 3.4 35.9 ± 4.3 37.3 ± 4.0
S n-3 6.9 ± 1.9 6.7 ± 2.0 4.2 ± 1.4 4.2 ± 1.3 9.8 ± 2.3 9.7 ± 2.2
S n-6/S n-3 ratio 5.4 ± 1.6 5.7 ± 2.2 7.5 ± 2.9 7.5 ± 2.7 3.9 ± 1.3 4.1 ± 1.2
Unsaturation indexc 134.3 ± 16.5 136.5 ± 13.6 213.2 ± 21.6 217.4 ± 16.7
a Data are based on 43 neonates from active-group (3 cord samples were lost) and 42 placebo-group and expressed as relative percentage of total fatty acids identiﬁed (%wt/
wt).
b No statistically signiﬁcant differences were found between the two groups when tested with an independent t-test.
c Unsaturation index is the sum of the % unsaturated fatty acids multiplied by their number of double bonds.
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The signiﬁcance of reduction in blood AA level in women
compromised by GDM is yet to be fully investigated. However,
because AA is a ubiquitous constituent of most tissues and plays an
important role in biological functions under normal physiological
conditions, there may be a need to provide AA in order to help
prevent the decline.
Nutritional intervention and epidemiological studies have re-
ported that increased intake of long-chain omega-3 fatty acids
during pregnancy reduces preterm births by prolonging gestation
period [26e29]. We have observed a similar trend in a small
number of pregnant women with type 2 diabetes [23]. Paradoxi-
cally, in the current study, the number of preterm births was higher
(statistically insigniﬁcant) in the active-group. To ﬁnd possible
explanations for the observation, past obstetrics histories of the
women who delivered prematurely were examined. In the active-
group, 8 of the 12 women who delivered early had obstetric com-
plications (pregnancy-induced hypertension, GDM, miscarriages)
in their previous pregnancies. There was only one womanwho had
a history of GDM in the placebo-group. Hence, it is possible that the
higher number of preterm births in the active-groupmay have been
a reﬂection of the predisposition of these women to a recurrent
preterm delivery due to genetic-environmental factors or uniden-
tiﬁed underlying medical conditions.
There is indication that the provision of DHA during pre and
postnatal period inﬂuences adiposity in infants [30,31] and pre-
school children [32,33]. We have assessed whether a similar effect
was apparent in this study. Shoulder, mid-arm and abdomen
circumference measurements were used as an indirect indictor of
adiposity. There was no difference in the values of the aforemen-
tioned parameters between the neonates born to the two groups of
mothers. This ﬁnding was not surprising because maternal sup-
plementation did not enhance fetal DHA status.
There was a high number of a delivery sample loss resulting
from unanticipated births before due date, women moving out of
the area without providing a contact address and too-busy labor or
delivery midwives to collect samples. This limitation would have
been minimized by recruiting additional midwives but it could not
be done because of ﬁnancial constraints. Another limitationwas the
inability to determine placental fatty acids and the activity and
expression of placental fatty acid binding and transport proteins.
Lastly, despite our efforts to obtain information about a habitualdiet of the women using a 4-day food diary, we were unable to
extract valuable data about their nutritional intake. This was
because a large number of diaries were returned incomplete.
This randomized, double-blind, placebo-controlled study dem-
onstrates that supplementation of womenwith GDM is effective in
enhancing maternal but not fetal DHA status. The failure of the
supplementation to improve the level of fetal DHA is of some
concern because the offspring of womenwith GDM are bornwith a
lower level of the nutrient and the condition is thought to be
associated with a risk of neuro-developmental deﬁcits. It is plau-
sible that maternal supplementation with more than 600 mg of
DHA may trickle down to the fetus and mitigate the insufﬁciency.
Regardless, we suggest that babies of women with GDM, particu-
larly those not suckling, similar to the babies born prematurely
require formula milk fortiﬁed with a higher level of DHA.Statement of authorship
YM and KG conceived the idea and designed the study. OD
contributed clinical aspect of the study design. YM prepared the
protocols, performed data analysis and its interpretation and
drafted the manuscript. KG contributed to the interpretation of
ﬁndings. JH and IN recruited and followed up the patients, collected
biological samples and clinical and demographic information
relevant to the study. SE and ASB carried out sample processing and
fatty acid analysis. All authors approved the ﬁnal manuscript.Funding sources
The study was supported by research grants from FP6 Marie
Curie Actions-Transfer of Knowledge (MTKD-CT-2005-029914),
Foyle Foundation, NewhamUniversity Hospital NHS Trust, Diabetes
Research Network (North East London Diabetes Local Research
Network), Equazen/Vifor Pharma Ltd., London Metropolitan Uni-
versity, Sir Halley Stewart Trust, The Mother and Child Foundation,
Letten Foundation and personal donation from Emeritus Professor
Clara Lowy. The supplements (Mumomega® and placebo) used in
this study were prepared and provided by Equazen/Vifor Pharma
Ltd. free of charge. The funding organizations and supplement
supplier played no role in the design of the study, analysis, inter-
pretation of data, or preparation of the manuscript.
Y. Min et al. / Clinical Nutrition 35 (2016) 608e614614
Author's Personal CopyConﬂict of interest statement
All authors declare that there is no competing ﬁnancial interest
in relation to this work.
Acknowledgments
The authors thank all the women and their families for
participating in the study, Vasu Chauhan and her staffs at the Pa-
thology Laboratory (Newham University Hospital) for processing
night delivery samples, the midwives and staffs at the Maternity
Services (NewhamUniversity Hospital) for their valuable assistance
in the recruitment and delivery sample collection, Ambreen Solangi
for her administrative assistance and Katia Mariniello and Amanda
Hallot for their contribution to the sample processing during the
initial stage of the study.
References
[1] Yessoufou A, Moutairou K. Maternal diabetes in pregnancy: early and long-
term outcomes on the offspring and the concept of "metabolic memory. Exp
Diabetes Res 2011;2011:218598.
[2] Buckley BS, Harreiter J, Damm P, Corcoy R, Chico A, Simmons D, et al., DALI
Core Investigator Group. Gestational diabetes mellitus in Europe: prevalence,
current screening practice and barriers to screening. A review. Diabet Med
2012;29(7):844e54.
[3] Green JR, Pawson IG, Schumacher LB, Perry J, Kretchmer N. Glucose tolerance
in pregnancy: ethnic variation and inﬂuence of body habitus. Am J Obstet
Gynecol 1990;163(1 Pt 1):86e92.
[4] Min Y, Ghebremeskel K, Lowy C, Thomas B, Crawford MA. Adverse effect of
obesity on red cell membrane arachidonic and docosahexaenoic acids in
gestational diabetes. Diabetologia 2004;47(1):75e81.
[5] Min Y, Nam JH, Ghebremeskel K, Kim A, Crawford M. A distinctive fatty acid
proﬁle in circulating lipids of Korean gestational diabetics: a pilot study.
Diabetes Res Clin Pract 2006;73(2):178e83.
[6] Wijendran V, Bendel RB, Couch SC, Philipson EH, Cheruku S, Lammi-Keefe CJ.
Fetal erythrocyte phospholipid polyunsaturated fatty acids are altered in
pregnancy complicated with gestational diabetes mellitus. Lipids 2000;35(8):
927e31.
[7] Min Y, Lowy C, Ghebremeskel K, Thomas B, Bitsanis D, Crawford MA. Fetal
erythrocyte membrane lipids modiﬁcation: preliminary observation of an
early sign of compromised insulin sensitivity in offspring of gestational dia-
betic women. Diabet Med 2005;22(7):914e20.
[8] Ruzickova J, Rossmeisl M, Prazak T, Flachs P, Sponarova J, Veck M, et al.
Omega-3 PUFA of marine origin limit diet-induced obesity in mice by
reducing cellularity of adipose tissue. Lipids 2004;39(12):1177e85.
[9] Gonzalez-Periz A, Horrillo R, Ferre N, Gronert K, Dong B, Moran-Salvador E,
et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by
omega-3 fatty acids: a role for resolvins and protectins. FASEB J 2009;23(6):
1946e57.
[10] Ramanadham S, Zhang S, Ma Z, Wohltmann M, Bohrer A, Hsu FF, et al. Delta6-,
stearoyl CoA-, and Delta5-desaturase enzymes are expressed in beta-cells and
are altered by increases in exogenous PUFA concentrations. Biochim Biophys
Acta 2002;1580(1):40e56.
[11] Uauy R, Mena P, Rojas C. Essential fatty acids in early life: structural and
functional role. Proc Nutr Soc 2000;59(1):3e15.
[12] Koletzko B, Agostoni C, Carlson SE, Clandinin T, Hornstra G, Neuringer M, et al.
Long chain polyunsaturated fatty acids (LC-PUFA) and perinatal development.
Acta Paediatr 2001;90(4):460e4.
[13] Araújo JR, Correia-Branco A, Ramalho C, Keating E, Martel F. Gestational dia-
betes mellitus decreases placental uptake of long-chain polyunsaturated fatty
acids: involvement of long-chain acyl-CoA synthetase. J Nutr Biochem
2013;24(10):1741e50.
[14] Pagan A, Prieto-Sanchez MT, Blanco-Carnero JE, Gil-Sanchez A, Parrilla JJ,
Demmelmair H, et al. Materno-fetal transfer of docosahexaenoic acid isimpaired by gestational diabetes mellitus. Am J Physiol Endocrinol Metab
2013;305(7):E826e33.
[15] Faul F, Erdfelder E, Lang A-G, Buchner A. G*Power 3: a ﬂexible statistical
power analysis program for the social, behavioral, and biomedical sciences.
Behav Res Methods 2007;39:175e91.
[16] Shohet SB. The apparent transfer of fatty acid from phosphatidylcholine to
phosphatidylethanolamine in human erythrocytes. J Lipid Res 1971;12(2):
139e42.
[17] Lubin B, Kuypers FA, Chiu D. Red cell membrane lipid dynamics. Alan R Liss Inc
1989:507e24.
[18] Kleinfeld AM, Storms S, Watts M. Transport of long-chain native fatty acids
across human erythrocyte ghost membranes. Biochemistry 1998;37(22):
8011e9.
[19] Luxwolda MF, Kuipers RS, Sango WS, Kwesigabo G, Dijck-Brouwer DA,
Muskiet FA. A maternal erythrocyte DHA content of approximately 6 g% is the
DHA status at which intrauterine DHA biomagniﬁcations turns into bio-
attenuation and postnatal infant DHA equilibrium is reached. Eur J Nutr
2012;51(6):665e75.
[20] Escolano-Margarit MV, Campoy C, Ramírez-Tortosa MC, Demmelmair H,
Miranda MT, Gil A, et al. Effects of ﬁsh oil supplementation on the fatty acid
proﬁle in erythrocyte membrane and plasma phospholipids of pregnant
women and their offspring: a randomised controlled trial. Br J Nutr
2013;109(9):1647e56.
[21] Miles EA, Noakes PS, Kremmyda LS, Vlachava M, Diaper ND, Rosenlund G,
et al. The salmon in pregnancy study: study design, subject characteristics,
maternal ﬁsh and marine n-3 fatty acid intake, and marine n-3fatty acid status
in maternal and umbilical cord blood. Am J Clin Nutr 2011;94(6 Suppl.).
1986S-1992S.
[22] Simopoulos AP, Leaf A, Salem Jr N. Workshop on the essentiality of and rec-
ommended dietary intakes for omega-6 and omega-3 fatty acids. Asia Pac J
CLini Nutr 1999;8(4):300e1.
[23] Min Y, Djahanbakhch O, Hutchinson J, Bhullar AS, Raveendran M, Hallot A,
et al. Effect of docosahexaenoic acid-enriched ﬁsh oil supplementation in
pregnant women with type 2 diabetes on membrane fatty acids and fetal
body composition-double-blinded randomized placebo-controlled trial. Dia-
bet Med 2014;31(11):1331e40.
[24] Salge AK, Rocha KM, Xavier RM, Ramalho WS, Rocha EL, Guimar~aes JV, et al.
Macroscopic placental changes associated with fetal and maternal events in
diabetes mellitus. Clin (Sao Paulo) 2012;67(10):1203e8.
[25] Arterburn LM, Hall EB, Oken H. Distribution, interconversion, and dose
response of n-3 fatty acids in humans. Am J Clin Nutr 2006;83(6 Suppl.).
1467S-1476S.
[26] Olsen SF, Sørensen JD, Secher NJ, Hedegaard M, Henriksen TB, Hansen HS,
et al. Randomised controlled trial of effect of ﬁsh-oil supplementation on
pregnancy duration. Lancet 1992;339(8800):1003e7.
[27] Olsen SF, Secher NJ. Low consumption of seafood in early pregnancy as a risk
factor for preterm delivery: prospective cohort study. BMJ 2002;324(7335):
447.
[28] Klebanoff MA, Harper M, Lai Y, Thorp Jr J, Sorokin Y, Varner MW, et al., Eunice
Kennedy Shriver National Institute of Child Health and Human Development
(NICHD) Maternal-Fetal Medicine Units Network (MFMU). Fish consumption,
erythrocyte fatty acids, and preterm birth. Obstet Gynecol 2011;117(5):
1071e7.
[29] Carlson SE, Colombo J, Gajewski BJ, Gustafson KM, Mundy D, Yeast J, et al. DHA
supplementation and pregnancy outcomes. Am J Clin Nutr 2013;97(4):
808e15.
[30] Groh-Wargo S, Jacobs J, Auestad N, O'Connor DL, Moore JJ, Lerner E. Body
composition in preterm infants who are fed long-chain polyunsaturated fatty
acids: a prospective, randomized, controlled trial. Pediatr Res 2005;57(5 Pt 1):
712e8.
[31] Lucia Bergmann R, Bergmann KE, Haschke-Becher E, Richter R,
Dudenhausen JW, Barclay D, et al. Does maternal docosahexaenoic acid sup-
plementation during pregnancy and lactation lower BMI in late infancy?
J Perinat Med 2007;35(4):295e300.
[32] Donahue SM, Rifas-Shiman SL, Gold DR, Jouni ZE, Gillman MW, Oken E. Pre-
natal fatty acid status and child adiposity at age 3 y: results from a US
pregnancy cohort. Am J Clin Nutr 2011;93(4):780e8.
[33] Pedersen L, Lauritzen L, Brasholt M, Buhl T, Bisgaard H. Polyunsaturated fatty
acid content of mother's milk is associated with childhood body composition.
Pediatr Res 2012;72(6):631e6.
